Welcome to our dedicated page for Centessa Pharmaceuticals Plc news (Ticker: CNTA), a resource for investors and traders seeking the latest updates and insights on Centessa Pharmaceuticals Plc stock.
Centessa Pharmaceuticals plc (Nasdaq: CNTA) is a clinical-stage pharmaceutical company centered on developing orexin receptor 2 (OX2R) agonist therapies for sleep–wake and neuroscience-related disorders. The CNTA news feed highlights company announcements that track the progress of this multi-asset OX2R pipeline and related corporate developments.
Investors and followers of Centessa can use this page to review news about the Phase 2a CRYSTAL‑1 study of ORX750 in narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), as well as updates on the Phase 1 program for ORX142 in healthy volunteers and IND-enabling work for ORX489 in neuropsychiatric disorders. The company’s releases also describe preclinical data on additional OX2R agonists, including findings in animal models relevant to neuropsychiatric indications.
Beyond clinical milestones, CNTA news items cover capital markets and corporate events such as public offerings of American Depositary Shares, at-the-market sales agreements, participation in healthcare and investor conferences, and leadership changes reported via press release and Form 8‑K. These disclosures provide context on how Centessa funds and organizes its development activities.
This news page aggregates official communications from Centessa and related SEC-reported events, allowing readers to follow clinical data readouts, regulatory milestones like IND clearance, financing transactions and strategic updates around the company’s orexin-focused franchise. For ongoing research into CNTA, this stream offers a centralized view of the company’s reported progress and key announcements over time.
Centessa Pharmaceuticals (NASDAQ: CNTA) successfully completed an initial public offering (IPO), raising gross proceeds of $379.5 million to support its clinical and preclinical programs. The leadership team has been strengthened with key appointments in various executive roles. Financial results for Q2 2021 show a cash position of $613.8 million, enabling operations through the end of 2023. R&D expenses rose to $18.1 million due to an expanded portfolio, while net loss increased to $41.5 million or $0.65 per share.
Centessa Pharmaceuticals (Nasdaq: CNTA) announced that CEO Saurabh Saha will participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, at 5:30 p.m. ET. The company focuses on developing new medicines through an asset-centric model, emphasizing specialized teams for diverse therapeutic areas, including oncology, hematology, and immunology. Centessa owns ten asset-centric companies, ranging from discovery to late-stage development, allowing for strategic resource allocation and shared infrastructure.
Citi has been appointed by Centessa Pharmaceuticals to serve as the depositary bank for its American Depositary Receipt (ADR) program. Centessa's American Depositary Shares (ADSs) are listed on the Nasdaq under the symbol 'CNTA'. Dirk Jones from Citi expressed enthusiasm for supporting Centessa's ADR program and enhancing investor outreach through their global equity distribution network. Centessa aims to innovate the drug development process by applying an asset-centric R&D model across its ten subsidiaries, backed by centralized infrastructure.
Centessa Pharmaceuticals announced the full exercise of the underwriters' option to purchase an additional 2,475,000 American Depositary Shares (ADSs) at the IPO price of $20.00, raising total gross proceeds to $379.5 million. The IPO closing occurred on June 2, 2021, with the additional ADSs issued today. This offering reflects the firm's asset-centric model aimed at developing impactful medicines. Morgan Stanley, Goldman Sachs, Jefferies, and Evercore ISI managed the offering. A registration statement was declared effective by the SEC on May 27, 2021.
Centessa Pharmaceuticals announced the pricing of its initial public offering of 16,500,000 American Depositary Shares (ADSs) at $20.00 per ADS, totaling approximately $330 million in gross proceeds. The offering is expected to close on June 2, 2021, pending customary conditions, with shares trading on Nasdaq under the symbol "CNTA" starting May 28, 2021. The underwriters have a 30-day option to purchase an additional 2,475,000 ADSs. Morgan Stanley, Goldman Sachs, Jefferies, and Evercore ISI are managing the offering.